Renal Insufficiency in Concert with Renin angiotensin aldosterone Inhibition Is a Major Risk Factor for Hyperkalemia Associated with Low dose Trimethoprim sulfamethoxazole in Adults.
OBJECTIVE Low dose trimethoprim sulfamethoxazole (TMP SMX) is commonly used to prevent pneumocystis pneumonia in daily practice. Previous reports have shown a relationship between high or standard dose of TMP SMX and hyperkalemia, however it remains unclear whether this is true for low dose TMP SMX. In this study we sought to determine the risk factors for hyperkalemia associated with low dose TMP SMX. METHODS In this retrospective cohort study, 186 consecutive adult patients who received TMP SMX as prophylaxis for pneumocystis pneumonia from January 2014 to January 2015 were evaluated. Data on the patients' age, gender, baseline estimated glomerular filtration rate (eGFR) baseline serum potassium, maximum serum potassium, duration reaching the maximal serum potassium level, dosage, and concomitant use of angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) b blockers, non steroidal anti inflammatory drugs and potassium sparing diuretics were retrospectively collected. Hyperkalemia was defined as a serum potassium level =5 mEq/L. Univariate and multivariate analyses were performed. RESULTS The median age of the patients was 66 years and 51.1% were men. Hyperkalemia associated with low dose TMP SMX was observed in 32 patients (17.2% The median duration to reach the maximal serum potassium level was 12 days. The multivariate logistic regression analysis identified renal insufficiency to be a major risk factor for hyperkalemia associated with low dose TMP SMX (eGFR <60 mL/min/1.73 m(2) adjusted OR 4.62) Moreover, in the subpopulation of patients with renal insufficiency, ACEi/ARB use was considered to be a major risk factor for hyperkalemia (adjusted OR 3.96) CONCLUSION Renal insufficiency in concert with ACEi/ARB use is a major risk factor for hyperkalemia induced by low dose TMP SMX.
Internal medicine